Therapeutic approaches for combating Pseudomonas aeruginosa infections
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Pseudomonas aeruginosa is an opportunistic pathogen responsible for acute hospital-acquired infections. This review described various therapeutic approaches to treat infections caused by P. aeruginosa, including conventional therapy, novel antibiotic treatments and treatments other than antibiotics. Most of the developments are still in research that will provide novel treatment options in future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“P. aeruginosa is also one of the top-listed pathogens causing hospital-acquired infections, which are widely found in medical devices (ventilation) because they tend to thrive on wet surfaces.7”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Function of Pseudomonas Porins in Uptake and Efflux
Hancock, R. E. W., & Brinkman, F. S. L. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160310 · Cited by 319
Role of Iron Uptake Systems in Pseudomonas aeruginosa Virulence and Airway Infection
Minandri, F., Imperi, F., Frangipani, E., Bonchi, C., Visaggio, D., Facchini, M., Pasquali, P., Bragonzi, A., & Visca, P. (2016) · Infection and Immunity · doi:10.1128/iai.00098-16 · Cited by 228
Research works printed but not linked: 65
- Burrows, 2018, The therapeutic pipeline for Pseudomonas aeruginosa infections, ACS Infect Dis, 4, 1041, 10.1021/acsinfecdis.8b00112 · DOI · Paper page
- Sadikot, 2005, Pathogen–host interactions in Pseudomonas aeruginosa pneumonia, Am J Respir Crit Care Med, 171, 1209, 10.1164/rccm.200408-1044SO · DOI · Paper page
- Moore, 2011, Treatment strategies and recommendations for Pseudomonas aeruginosa infections, Clin Lab Sci, 24, 52, 10.29074/ascls.24.1.52 · doi:10.29074/ascls.24.1.52
- Lister, 2009, Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms, Clin Microbiol Rev, 22, 582, 10.1128/CMR.00040-09 · DOI · Paper page
- Breidenstein, 2011, Pseudomonas aeruginosa: all roads lead to resistance, Trends Microbiol, 19, 419, 10.1016/j.tim.2011.04.005 · DOI · Paper page
- Zavascki, 2010, Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy, Expert Rev Anti Infect Ther, 8, 71, 10.1586/eri.09.108 · DOI · Paper page
- Taylor, 2014, Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies, J Biotechnol, 191, 121, 10.1016/j.jbiotec.2014.09.003 · DOI · Paper page
- Pang, 2019, Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies, Biotechnol Adv, 37, 177, 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
- Pachori, 2019, Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review, Genes Dis, 6, 109, 10.1016/j.gendis.2019.04.001 · DOI · Paper page
- Lima, 2020, β-Lactam antibiotics: an overview from a medicinal chemistry perspective, Eur J Med Chem, 208, 1, 10.1016/j.ejmech.2020.112829 · DOI · Paper page
- Becker, 2013, Aminoglycoside antibiotics in the 21st century, ACS Chem Biol, 8, 105, 10.1021/cb3005116 · DOI · Paper page
- Pham, 2019, Quinolone antibiotics, Med Chem Commun, 10, 1719, 10.1039/C9MD00120D · DOI · Paper page
- Arnold, 2007, Polymyxin antibiotics for gram-negative infections, Am J Health Syst Pharm, 64, 819, 10.2146/ajhp060473 · DOI
- Sharma, 2021, Antibiotic adjuvants: a promising approach to combat multidrug-resistant bacteria, Curr Drug Targets, 22, 1334, 10.2174/1389450122666210120084406 · DOI
- Amaral, 2014, Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them, Front Pharmacol, 4, 1, 10.3389/fphar.2013.00168 · DOI · Paper page
- Venter, 2015, RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition, Front Microbiol, 6, 1, 10.3389/fmicb.2015.00377 · DOI · Paper page
- Auda, 2020, Efflux pumps of Gram-negative bacteria in brief, Gene Rep, 20, 1
- McCarthy, 2015, Pseudomonas aeruginosa: evolution of antimicrobial resistance and implications for therapy, Semin Respir Crit Care Med, 36, 44, 10.1055/s-0034-1396907 · DOI
- Morita, 2012, MexXY multidrug efflux system of Pseudomonas aeruginosa, Front Microbiol, 3, 1, 10.3389/fmicb.2012.00408 · DOI · Paper page
- Wolter, 2013, Mechanisms of β-lactam resistance among Pseudomonas aeruginosa, Curr Pharmaceut Des, 19, 209, 10.2174/138161213804070311 · DOI · Paper page
- Pachori, 2019, Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review, Genes Dis, 6, 109, 10.1016/j.gendis.2019.04.001 · DOI · Paper page
- Furtado, 2007, Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa, Int J Antimicrob Agents, 30, 315, 10.1016/j.ijantimicag.2007.05.017 · DOI
- Bassetti, 2018, How to manage Pseudomonas aeruginosa infections, Drugs Context, 7, 1, 10.7573/dic.212527 · DOI · Paper page
- Ramirez, 2010, Aminoglycoside modifying enzymes, Drug Resist Updates, 13, 151, 10.1016/j.drup.2010.08.003 · DOI · Paper page
- Chevalier, 2017, Structure, function and regulation of Pseudomonas aeruginosa porins, FEMS Microbiol Rev, 41, 1, 10.1093/femsre/fux020 · DOI · Paper page
- Purssell, 2013, Functional characterization of the NfxB repressor of the mexCD–oprJ multidrug efflux operon of Pseudomonas aeruginosa, Microbiol, 159, 1, 10.1099/mic.0.069286-0 · DOI · Paper page
- Kamali, 2020, Evaluation of antimicrobial resistance, biofilm-forming potential, and the presence of biofilm-related genes among clinical isolates of Pseudomonas aeruginosa, BMC Res Notes, 13, 1, 10.1186/s13104-020-4890-z · DOI · Paper page
- Rasamiravaka, 2015, The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms, BioMed Res Int, 1, 10.1155/2015/759348 · DOI · Paper page
- Grassi, 2017, Generation of persister cells of Pseudomonas aeruginosa and Staphylococcus aureus by chemical treatment and evaluation of their susceptibility to membrane-targeting agents, Front Microbiol, 8, 1, 10.3389/fmicb.2017.01917 · DOI · Paper page
- Chatterjee, 2016, Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options, Int J Med Microbiol, 306, 48, 10.1016/j.ijmm.2015.11.004 · DOI · Paper page
- Chahine, 2010, Doripenem: a new carbapenem antibiotic, Am J Health Syst Pharm, 67, 2015, 10.2146/ajhp090672 · doi:10.2146/ajhp090672
- Queenan, 2010, Hydrolysis and inhibition profiles of β-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem, Antimicrob Agents Chemother, 54, 565, 10.1128/AAC.01004-09 · DOI · Paper page
- Bazan, 2011, Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime, Med Clin North Am, 95, 743, 10.1016/j.mcna.2011.03.009 · doi:10.1016/j.mcna.2011.03.009
- Cox, 2018, Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes, ACS Infect Dis, 4, 980, 10.1021/acsinfecdis.8b00001 · DOI
- Eljaaly, 2019, Plazomicin: a novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections, Drugs, 79, 243, 10.1007/s40265-019-1054-3 · DOI · Paper page
- Cigana, 2016, Efficacy of the novel antibiotic POL7001 in preclinical models of Pseudomonas aeruginosa pneumonia, Antimicrob Agents Chemother, 60, 4991, 10.1128/AAC.00390-16 · DOI
- Werneburg, 2012, Inhibition of lipopolysaccharide transport to the outer membrane in Pseudomonas aeruginosa by peptidomimetic antibiotics, Chembiochem, 13, 1767, 10.1002/cbic.201200276 · DOI · Paper page
- Freinkman, 2012, Regulated assembly of the transenvelope protein complex required for lipopolysaccharide export, Biochemistry, 51, 4800, 10.1021/bi300592c · DOI · Paper page
- Srinivas, 2010, Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa, Science, 327, 1010, 10.1126/science.1182749 · DOI · Paper page
- Zhanel, 2014, Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli, Drugs, 74, 31, 10.1007/s40265-013-0168-2 · DOI · Paper page
- Garazzino, 2020, Ceftolozane/tazobactam for treating children with exacerbations of cystic fibrosis due to Pseudomonas aeruginosa: a review of available data, Front Pediatr, 8, 1, 10.3389/fped.2020.00173 · DOI
- Shirley, 2018, Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections, Drugs, 78, 675, 10.1007/s40265-018-0902-x · DOI · Paper page
- Zhanel, 2013, Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination, Drugs, 72, 159, 10.1007/s40265-013-0013-7 · DOI · Paper page
- Wright, 2017, New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?, Clin Microbiol Infect, 23, 704, 10.1016/j.cmi.2017.09.001 · DOI · Paper page
- El Solh, 2009, Update on the treatment of Pseudomonas aeruginosa pneumonia, J Antimicrob Chemother, 64, 229, 10.1093/jac/dkp201 · DOI · Paper page
- Wagner, 2016, Novel strategies for the treatment of Pseudomonas aeruginosa infections, J Med Chem, 59, 5929, 10.1021/acs.jmedchem.5b01698 · DOI · Paper page
- Fothergill, 2012, Novel therapeutic strategies to counter Pseudomonas aeruginosa infections, Expert Rev Anti Infect Ther, 10, 219, 10.1586/eri.11.168 · DOI · Paper page
- Kalia, 2019, Quorum sensing inhibitors as antipathogens: biotechnological applications, Biotechnol Adv, 37, 68, 10.1016/j.biotechadv.2018.11.006 · DOI · Paper page
- Gökalsın, 2017, Reducing virulence and biofilm of Pseudomonas aeruginosa by potential quorum sensing inhibitor carotenoid: zeaxanthin, Microb Ecol, 74, 466, 10.1007/s00248-017-0949-3 · DOI
- Kitao, 2018, Molecular insights into function and competitive inhibition of Pseudomonas aeruginosa multiple virulence factor regulator, mBio, 9, 1, 10.1128/mBio.02158-17 · DOI
- Johansson, 2008, Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB, Chem Biol, 15, 1249, 10.1016/j.chembiol.2008.10.009 · DOI · Paper page
- Kadam, 2011, A glycopeptide dendrimer inhibitor of the galactose-specific lectin LecA and Pseudomonas aeruginosa biofilms, Angew Chem Int Ed, 50, 10631, 10.1002/anie.201104342 · DOI
- Cheng, 2021, Constructing nanostructured functional film on EH40 steel surface for anti-adhesion of Pseudomonas aeruginosa, Surf Coating Technol, 405, 1, 10.1016/j.surfcoat.2020.126683 · DOI
- Mittal, 2009, Urinary tract infections caused by Pseudomonas aeruginosa: a minireview, J Infect Publ Health, 2, 101, 10.1016/j.jiph.2009.08.003 · DOI · Paper page
- Diggle, 2020, Microbe Profile: Pseudomonas aeruginosa: opportunistic pathogen and lab rat, Microbiology, 166, 30, 10.1099/mic.0.000860 · DOI · Paper page
- Chen, 2015, Composition, function, and regulation of T6SS in Pseudomonas aeruginosa, Microbiol Res, 172, 19, 10.1016/j.micres.2015.01.004 · DOI
- Sandri, 2018, Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice, Virulence, 9, 1008, 10.1080/21505594.2018.1489198 · DOI · Paper page
- Abbas, 2015, Inhibition of virulence factors of Pseudomonas aeruginosa by diclofenac sodium, Rom Arch Microbiol Immunol, 74, 79
- Sharma, 2021, Chemotherapeutic strategies for combating Staphylococcus aureus infections, Mini Rev Med Chem, 21, 1
- Waters, 2017, Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa, Thorax, 72, 666, 10.1136/thoraxjnl-2016-209265 · DOI · Paper page
- Torres-Barceló, 2014, A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages, PLoS One, 9, 1, 10.1371/journal.pone.0106628 · DOI · Paper page
- Pires, 2016, Genetically engineered phages: a review of advances over the last decade, Microbiol Mol Biol Rev, 80, 523, 10.1128/MMBR.00069-15 · DOI · Paper page
- Labrie, 2010, Bacteriophage resistance mechanisms, Nat Rev Microbiol, 8, 317, 10.1038/nrmicro2315 · DOI · Paper page
- Jeevanandam, 2018, Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations, Beilstein J Nanotechnol, 9, 1050, 10.3762/bjnano.9.98 · DOI · Paper page
- Döring, 2008, Vaccines and immunotherapy against Pseudomonas aeruginosa, Vaccine, 26, 1011, 10.1016/j.vaccine.2007.12.007 · doi:10.1016/j.vaccine.2007.12.007
Cited by
Qin, S., Xiao, W., Zhou, C., Pu, Q., Deng, X., Lan, L., Liang, H., Song, X., & Wu, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01056-1 · Cited by 1,703
Metadata
- Authors
- Jangra, V., Sharma, N., & Chhillar, A. K.
- Venue
- Microbes and Infection
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 24
- Issue
- 4
- Pages
- 104950
- ISSN
- 1286-4579
- Cited by
- 66
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 579 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.